Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: J Autoimmun. 2019 Mar 8;100:52–61. doi: 10.1016/j.jaut.2019.02.006

Fig. 3. AS101 inhibits effector T cell polarization and acquisition of pathogenicity in vitro.

Fig. 3.

R161H LN cells were stimulated with 2 μg/ml IRBP161-180 under Th1 or Th17 polarizing conditions with PBS or various concentrations of AS101 (0.1, 0.3, or 1 μg/ml) for 72 h. (A) After polarization towards Th1 or Th17, the CD3+CD4+ population was assessed for IFN-γ and IL-17A expressing cells, respectively, by flow cytometry. Data shown as mean ± SEM from 3 independent experiments. *p<0.05; **p<0.01; ***p<0.001 vs. PBS. (B) After Th1 or Th17 polarization with PBS or 1 μg/ml of AS101, viable cells were harvested in Lympholyte M, and Th1 cells (1 million cells/mouse) or Th17 cells (3 million cells/mouse) were adoptively transferred i.p. into naïve B10.RIII recipient mice. Graph shows fundoscopy scores of eyes of B10.RIII recipient mice on day 10. Number of animals: Th1 PBS, n=9; Th1 AS, n=10; Th17 PBS, n=10; Th17 AS, n=10. Data shown as mean ± SEM from 3 independent experiments *p<0.05 vs. Th17 PBS group **p<0.01 vs. Th1 PBS group.